Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company’s Board of Directors and will step down from the Board to join ALX as Interim Chief Medical Officer
ALX Oncology Holdings Inc. a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, announced the appointment of Dr. Klencke to the role of Interim Chief Medical Officer (CMO) on a full-time basis. Dr. Alan Sandler is departing from the role of CMO and will return to his former position on the ALX Oncology Board of Directors (BOD), where he previously served.
Health Technology Insights: Valvoline, Blood Cancer United & Hendrick Motorsports Unite
“Dr. Barbara Klencke’s extensive expertise in driving cancer innovation is evidenced by her substantial contributions to the development and approval of numerous first-in-class therapies, making her well positioned to lead the execution of our Company’s near and longer-term milestones,” said Jason Lettmann, Chief Executive Officer at ALX Oncology. “As a current member of our BOD, she can immediately step into the Interim CMO role to implement our focused development strategy across both the evorpacept and ALX2004 clinical programs. Barbara brings a track record of success with early-stage companies having served as the CMO of Sierra Oncology from 2015 through its acquisition by GlaxoSmithKline (GSK) in 2022. We also thank Alan for his instrumental role as CMO and look forward to his continued contributions to the Company as he returns to his role as a Director on our Board.”
Health Technology Insights: Lōvu Health Raises $8Million Series A to Transform Maternal Care
“As a member of ALX Oncology’s Board, I’ve witnessed firsthand the remarkable progress across both the evorpacept and ALX2004 clinical programs,” said Dr. Klencke. “As I step into my new role as Interim CMO, I look forward to working alongside this experienced leadership team as they continue the development of their highly differentiated CD47 blocker and novel epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC). I am excited to drive these molecules forward and deliver on ALX’s commitment to bring clinically meaningful innovation to patients in need.”
An ALX Board member since January 2025, Dr. Klencke has more than 30 years of experience in patient care, academic and scientific research, and clinical drug development in hematology and oncology. She has deep R&D expertise and has made significant contributions to the development, approval and commercialization of numerous oncology products through various executive leadership roles at a range of small, mid-sized and large biotech companies including Sierra Oncology, Onyx Pharmaceuticals (acquired by Amgen) and Genentech, a member of the Roche Group. Prior to entering the biotechnology industry, Dr. Klencke served as an Assistant Clinical Professor of Medicine, Division of Hematology and Oncology, at the University of California, San Francisco, where she previously completed her training in hematology, oncology and internal medicine. She holds a Bachelor of Science degree from Indiana University and an M.D. from the University of California, Davis. In addition to ALX Oncology, Dr. Klencke is an independent board director of Xencor and TScan Therapeutics.
Health Technology Insights: Health Catalyst Names Ben Albert President and COO
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – GlobeNewswire
